OBJECTIVE: To assess the effect of hypertension on the development of renal functional deterioration, end stage renal disease and death in patients with systemic lupus erythematosus (SLE). METHODS: Person-years analysis using regression techniques to adjust for other baseline risk factors for adverse renal and patient survival outcomes. RESULTS: Six hundred eighty-five patients with SLE were followed for a total of 4,137 person-years. The risk of renal deterioration (doubling of serum creatinine) and endstage renal disease (ESRD) both increased with increasing baseline mean arterial pressure (MAP) (both p > 0.05). Even after adjustment for age, sex, baseline serum creatinine, C3, erythrocyte sedimentation rate, hematocrit, anti-DNA antibodies, and proteinuria, those in the highest quartile of MAP had 2.3 times the odds of renal deterioration at 12 months and 4.6 times the odds of ESRD compared to those in the lowest quartile of MAP (both p < 0.01 comparing highest to lowest quartile of MAP). Also, hypertension increased the risk of mortality, especially between one and 2 years after blood pressure determination. The effect of hypertension was also independent of corticosteroid dose. CONCLUSION: In patients with SLE, hypertension is a potent independent risk factor for adverse renal outcomes, and it also increases the risk of death.
OBJECTIVE: To assess the effect of hypertension on the development of renal functional deterioration, end stage renal disease and death in patients with systemic lupus erythematosus (SLE). METHODS:Person-years analysis using regression techniques to adjust for other baseline risk factors for adverse renal and patient survival outcomes. RESULTS: Six hundred eighty-five patients with SLE were followed for a total of 4,137 person-years. The risk of renal deterioration (doubling of serum creatinine) and endstage renal disease (ESRD) both increased with increasing baseline mean arterial pressure (MAP) (both p > 0.05). Even after adjustment for age, sex, baseline serum creatinine, C3, erythrocyte sedimentation rate, hematocrit, anti-DNA antibodies, and proteinuria, those in the highest quartile of MAP had 2.3 times the odds of renal deterioration at 12 months and 4.6 times the odds of ESRD compared to those in the lowest quartile of MAP (both p < 0.01 comparing highest to lowest quartile of MAP). Also, hypertension increased the risk of mortality, especially between one and 2 years after blood pressure determination. The effect of hypertension was also independent of corticosteroid dose. CONCLUSION: In patients with SLE, hypertension is a potent independent risk factor for adverse renal outcomes, and it also increases the risk of death.
Authors: S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980
Authors: S Jacobsen; J Petersen; S Ullman; P Junker; A Voss; J M Rasmussen; U Tarp; L H Poulsen; G van Overeem Hansen; B Skaarup; T M Hansen; J Pødenphant; P Halberg Journal: Clin Rheumatol Date: 1998 Impact factor: 2.980
Authors: Sumapa Chaiamnuay; Ana M Bertoli; Jeffrey M Roseman; Gerald McGwin; Mandar Apte; Sergio Durán; Luis M Vilá; John D Reveille; Graciela S Alarcón Journal: Ann Rheum Dis Date: 2006-11-15 Impact factor: 19.103
Authors: George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas Journal: Ann Rheum Dis Date: 2012-07-31 Impact factor: 19.103